Long-term, observational cohort study of adults with plaque psoriasis (PsO), who are new users of deucravacitinib, tumour necrosis factor inhibitor (TNFi) biologics, non-TNFi biologics, or non-biologic therapies in the real-world clinical setting

Study identification

• EU PAS number:
  EUPAS1000000659
• Study ID:
  1000000659
• Official title and acronym:
  Long-term, observational cohort study of adults with plaque psoriasis (PsO), who are new users of deucravacitinib, tumour necrosis factor inhibitor (TNFi) biologics, non-TNFi biologics, or non-biologic therapies in the real-world clinical setting
• DARWIN EU® study:
  No
• Study countries:
  Denmark

  Finland

  France

  Germany

  Norway

  Spain
• Study status:
  Planned

Research institutions and networks

Institutions

University of Southern Denmark (SDU)

Denmark

Bordeaux PharmacoEpi, University of Bordeaux

France

The Norwegian Institute of Public Health

Norway

University Medical Centre Hamburg-Eppendorf

Germany

Spanish Academy of Dermatology and Venereology (AEDV)

University of Eastern Finland (UEF)

Networks

The SIGMA Consortium (SIGMA)

Denmark

European Union

France

Germany

Italy

Netherlands

Norway

Spain

Sweden

United Kingdom

Study timelines

Date when funding contract was signed

Actual:06/01/2025

Study start date

Planned:15/12/2025

Date of final study report

Planned:24/12/2032

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bristol-Myers Squibb

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)